PolyMedix to Review Full Results From Phase 2 Clinical Trial With PMX-30063 Defensin-Mimetic Antibiotic – Yahoo Finance

RADNOR, Pa., April 20, 2012 (GLOBE NEWSWIRE) — PolyMedix, Inc. (OTCBB:PYMX.OB – News), a biotechnology company focused on developing innovative therapeutic drugs to treat patients with serious acute-care conditions, has scheduled a conference …